Breast Implants Lymphoma Cancer
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
The Law Offices of Thomas J. Lamb represents people who have been harmed by unsafe medical products, including cases involving breast implants associated with lymphoma.
In more detail, the US Food and Drug Administration (FDA) has received reports about women who have had breast implant procedures done and, later, were diagnosed with these medical conditions:
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
- Anaplastic Large Cell Lymphoma (ALCL)
- Non-Hodgkin Lymphoma (also known as Non-Hodgkin’s Lymphoma, NHL, or just Lymphoma)
- T-cell Lymphoma
We encourage you to submit a Breast Implants Cancer Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible breast implants case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
- Summary of Information
- The Disease
- FDA Information
- Frequently Asked Questions
➤ About the Disease
➤ Risk Factors
We are here to help the women and families who have experienced this unfortunate situation. We have successfully handled personal injury and wrongful death cases for people throughout the country.
Our firm does not put its clients into large class actions lawsuits. Rather, an individual lawsuit is filed for each case. There are no costs associated with having us review your possible breast implants case.
Be assured that the information you provide to our law firm is treated as strictly confidential. Submitting a case evaluation does not obligate you to hire our law firm.
Lastly, we want you to know that you will get a reply directly from attorney Tom Lamb no later than the next business day.
Most Recent Article on This Topic
We have consistently provided updates on the situation of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) in relation to textured implants. Every article prior to this one has discussed how other countries have banned textured breast implants or how the FDA has been monitoring the issue. As of July 24, 2019 the FDA has finally joined in with the many other countries by recalling specific textured breast implants.
Allergan Implants Recall
We learn from the recent FDA News Release that the manufacturer at the forefront of this FDA decision is Allergan and the type of products are their BIOCELL textured breast implants and tissue expanders. Several products fall under this category:
- Natrelle Saline-Filled breast implants
- Natrelle Silicone-Filled breast implants
- Natrelle Inspira Silicone-Filled breast implants
- Natrelle 410 Highly Cohesive Automatically Shaped Silicone-Filled breast implants
- Natrelle 133 Plus Tissue Expander
- Natrelle 133 Tissue Expander with Suture Tabs
According to the news release, FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D., notes that even though the incident rate is rare, the fact that Allergan’s product in particular strongly correlated with BIA-ALCL diagnoses and deaths caused the recall action to be taken.
To read more of this article, click below:
Reason for Recall
As mentioned in our most recent previous article, “Statistics Show An Increased Risk For BIA-ALCL With Textured Implants”, the numbers for the population at risk is rising and so are the number of diagnoses. This FDA News Release gives the most current update:
573 unique cases globally of BIA-ALCL and 33 patient deaths, which reflect a significant increase in known cases of BIA-ALCL since the agency’s last update earlier this year —an increase of 116 new unique cases and 24 deaths. Specifically, of the 573 unique cases of BIA-ALCL, 481 are attributed to Allergan implants. Of the 33 patient deaths the FDA is reporting today, 12 of the 13 patients for which the manufacturer of the implant is known, are confirmed to have an Allergan breast implant at the time of their BIA-ALCL diagnosis.
Additionally, the recent FDA Safety Communication informs that:
The risk of BIA-ALCL with Allergan BIOCELL textured implants is approximately 6 times the risk of BIA-ALCL with textured implants from other manufacturers marketing in the U.S.
It has been known that other countries have already banned textured breast implants for quite some time. Allergan’s products in Europe, for example, were banned in 2018.
The New York Times just published an article, “Breast Implants Linked to Rare Cancer Are Recalled Worldwide“, where Dr. Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health, noted that, “The data regarding deaths was particularly informative of our decisions.”[Read article in full at original source]
Our earlier articles about this breast implants lymphoma cancer situation:
- Statistics Show An Increased Risk For BIA-ALCL With Textured Implants
- Textured Breast Implants Ban: Onto Australia
- FDA Fails When It Comes To Banning Textured Breast Implants
- Textured Breast Implants Bans on the Rise
- March 2019 FDA Meeting On Breast Implants: A Summary Of What You Need To Know
- Breast Implants FDA March 2019 Meeting: Lymphoma Cancer Was A Main Topic
- 2019 Discoveries and Warnings on Breast Implant-Associated Lymphoma
- Breast Implants Lymphoma Cancer Cases Update February 2019 – US & Canada
- Allergan Textured Breast Implants Recalled In Europe Due To BIA-ALCL
- FDA Provides Updated Number of Breast Implants Lymphoma Cancers
- New Data Released on Risk of Lymphoma Due to Breast Implants
- Breast Implant-Associated Lymphoma Diagnoses on the Rise
- What is the Risk of Death Due to Breast Implant-Associated Lymphoma?
- Treatments For Breast Implants Associated Lymphoma And Blood Cancer
- Breast Implants and Lymphoma: Who’s to Blame?
- Breast Implants Lymphoma Cancer: Diagnosis And Treatment Developments
- Breast Implant Lymphoma: Causes Uncertain, but Costs Undeniable
- March 2017 FDA Report: Breast Implants Linked To Lymphoma Blood Cancer
- Breast Implants Linked to Rare Lymphoma Blood Cancer